Prelude Therapeutics ( (PRLD) ) has provided an announcement.
Prelude Therapeutics announced its third quarter 2024 financial results, highlighting significant progress in its clinical programs. The company demonstrated clinical proof of concept with PRT3789, an IV SMARCA2 degrader, and initiated a trial for PRT7732, an oral SMARCA2 degrader. Prelude also presented promising preclinical data from its ADC platform and CDK9 inhibitor, PRT2527, with ongoing trials and collaborations fueling future developments. With a cash runway into 2026, Prelude remains committed to advancing its precision oncology pipeline.
Learn more about PRLD stock on TipRanks’ Stock Analysis page.
